KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

摘要: 2 Background: Efficacy analyses of the randomized phase III CRYSTAL trial have shown a significant improvement in progression-free survival (PFS), overall response, and curative surgery rate when adding cetuximab to FOLFIRI first-line treatment mCRC. Furthermore, KRAS mutation status has recently been relate outcome mCRC patients (pts) treated with as single agent or combination irinotecan. repeated evaluate influence pts without under controlled study conditions. Methods: Blocks from archived tumor material were available 587 1198 total pt population. Isolation genomic DNA was performed directly slides (3×10 μm). Determination done by qPCR-based analysis codons 12/13. The KRAS-evaluable (n=540) analyzed statistically effect stratified (wild-type [wt] or...